Sign In

Sarah Boyce

President and CEO of Avidity Biosciences, Inc.

Sarah Boyce is the President and CEO of Avidity Biosciences, Inc., a pioneering biopharmaceutical company focused on developing RNA therapeutics.12 She joined Avidity in October 2019, bringing over 25 years of global leadership experience in the pharmaceutical and biopharmaceutical industries.23

Career Highlights

Sarah Boyce's career spans several notable companies in the life sciences sector:

  • Avidity Biosciences: President and CEO (October 2019 - Present)4
  • Akcea Therapeutics: President and Board Member (April 2018 - September 2019)4
  • Ionis Pharmaceuticals: Chief Business Officer and Senior Vice President (January 2015 - April 2018)4
  • Forest Laboratories: Vice President - International Business Strategy and Operations (2012 - October 2014)4
  • Alexion Pharmaceuticals: VP - Nephrology (August 2010 - October 2011)4
  • Novartis Vaccines and Diagnostics: Various roles including Vice President, Global Program Head Pediatric and Specialty Business (1999 - 2010)4

Achievements at Avidity Biosciences

Under Sarah Boyce's leadership, Avidity Biosciences has:

  • Transitioned from a research-focused entity to a clinical-stage biopharmaceutical company1
  • Successfully completed a Series C funding round and an IPO2
  • Advanced multiple therapies into clinical development2
  • Expanded the company's proprietary RNA technology2

Education and Recognition

Sarah Boyce holds a BSc (Hons) degree in microbiology from the University of Manchester, England.2 Her achievements in the industry have been recognized with several accolades:

  • Named a Healthcare Technology Report Top 25 Biotech CEO in 20222
  • Recognized as one of the Fiercest Women in Life Sciences2

Board Memberships

In addition to her role at Avidity Biosciences, Sarah Boyce serves on the board of directors for several companies:

  • OmniAb, Inc.2
  • Contineum Therapeutics, Inc.2
  • Abcuro, Inc.2

Sarah Boyce's leadership at Avidity Biosciences is characterized by her focus on developing transformative treatments for rare diseases and her commitment to leveraging innovative RNA technology to address unmet medical needs.5

Highlights

Aug 27 · linkedin

So apparently it’s national dogs day. Unlike all my posts this one is personal and I’ll share some pics of my dogs. Brownie, the brown stray dog who was on death row before we adopted him. Cookie the OG dog and top dog a German sherpard, husky boxer rescue. Navi the poodle, who once had a fight with a bush you judge who won.

Aug 16 · linkedin

So wonderful to spend time with the incredible interns who joined us this summer. I am so grateful to Life Science Cares for project On-ramp, who helped us find this amazing group. We hosted 9 interns across the company in finance, project management, IT, Chemistry, Biology. Right here are future leaders in biotech.

Related Questions

What are some of the key achievements under Sarah Boyce's leadership at Avidity Biosciences?
How did Sarah Boyce's previous roles at companies like Ionis Pharmaceuticals and Novartis Oncology prepare her for her position at Avidity Biosciences?
What are the main therapeutic areas Avidity Biosciences is focusing on under Sarah Boyce's guidance?
How has Sarah Boyce's leadership impacted Avidity Biosciences' financial performance?
What makes Avidity Biosciences' proprietary RNA technology unique?
Sarah Boyce
Sarah Boyce, photo 1
Sarah Boyce, photo 2
Add to my network

Experience

President and CEO at Avidity Biosciences, Inc. since October 2019
President at Akcea Therapeutics, Chief Business Officer and Senior Vice President at Ionis Pharmaceuticals, Vice President - International business strategy and operations at Forest Laboratories

Education

Studied at The University of Manchester

Location

San Diego Metropolitan Area